Steadman Philippon Research Institute
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1988-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.sprivail.org
Clinical Trials
8
Active:3
Completed:1
Trial Phases
2 Phases
Phase 1:6
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Phase 1
6 (75.0%)Not Applicable
2 (25.0%)Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan
Phase 1
Recruiting
- Conditions
- Knee Arthroplasty, Total
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT06108063
- Locations
- πΊπΈ
The Steadman Clinic, Vail, Colorado, United States
Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan
Phase 1
Active, not recruiting
- Conditions
- Femoroacetabular Impingement
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 68
- Registration Number
- NCT05025956
- Locations
- πΊπΈ
The Steadman Clinic, Vail, Colorado, United States
Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
Phase 1
Active, not recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT04815902
- Locations
- πΊπΈ
The Steadman Clinic, Vail, Colorado, United States
Losartan to Improve Hip Microfracture
Phase 1
Terminated
- Conditions
- Hip Impingement SyndromeFibrosisHip OsteoarthritisCartilage Damage
- Interventions
- Other: Placebo
- First Posted Date
- 2019-12-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 1
- Registration Number
- NCT04212650
- Locations
- πΊπΈ
Steadman Philippon Research Institute, Vail, Colorado, United States
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Phase 1
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- Dietary Supplement: FisetinDrug: Placebo oral capsule
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Steadman Philippon Research Institute
- Target Recruit Count
- 75
- Registration Number
- NCT04210986
- Locations
- πΊπΈ
The Steadman Clinic, Vail, Colorado, United States
- Prev
- 1
- 2
- Next
News
DoD Awards $963K to SPRI for Breakthrough Extracellular Vesicle Study in Osteoarthritis Treatment
The U.S. Department of Defense awarded $962,977 to Steadman Philippon Research Institute for a year-long clinical study exploring enhanced extracellular vesicles as osteoarthritis therapy.